Preclinical glioma models in neuro-oncology: enhancing translational research.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
1
11
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
ppublish
Résumé
Gliomas represent approximately 25% of all primary brain and other central nervous system (CNS) tumors and 81% of malignant tumors. Unfortunately, standard treatment approaches for most CNS cancers have shown limited improvement in patient survival rates. The current drug development process has been plagued by high failure rates, leading to a shift towards human disease models in biomedical research. Unfortunately, suitable preclinical models for brain tumors have been lacking, hampering our understanding of tumor initiation processes and the discovery of effective treatments. In this review, we will explore the diverse preclinical models employed in neuro-oncology research and their contributions to translational science. By utilizing a combination of these preclinical models and fostering interdisciplinary collaborations, researchers can deepen their understanding of glioma brain tumors and develop novel therapeutic strategies to combat these devastating diseases. These models offer promising prospects for personalized and efficacious treatments for these challenging malignancies. Although it is unrealistic to fully replicate the complexity of the human body in vitro, the ultimate goal should be to achieve the closest possible resemblance to the clinical context.
Identifiants
pubmed: 37820088
doi: 10.1097/CCO.0000000000000997
pii: 00001622-202311000-00012
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-542Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States. Neuro Oncol 2020; 22: (Suppl 2): iv1–iv96.
Sun D, Gao W, Hu H, et al. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B 2022; 12:3049–3062.
Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. Br J Pharmacol 2011; 162:1239–1249.
Byrne AT, Alférez DG, Amant F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 2017; 17:254–268.
Robertson FL, Marqués-Torrejón MA, Morrison GM, et al. Experimental models and tools to tackle glioblastoma. Dis Model Mech 2019; 12: doi:10.1242/dmm.040386.
doi: 10.1242/dmm.040386
Golebiewska A, Fields RC. Advancing preclinical cancer models to assess clinically relevant outcomes. BMC Cancer 2023; 23:230.
Allen M, Bjerke M, Edlund H, et al. Origin of the U87MG glioma cell line: good news and bad news. Sci Transl Med 2016; 8:354re3.
Wenger A, Larsson S, Danielsson A, et al. Stem cell cultures derived from pediatric brain tumors accurately model the originating tumors. Oncotarget 2017; 8:18626–18639.
Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344:1396–1401.
Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756–760.
Rampazzo E, Persano L, Pistollato F, et al. Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis 2013; 4:e500.
Franceschi S, Civita P, Pasqualetti F, et al. Multiregional sequencing of IDH-WT glioblastoma reveals high genetic heterogeneity and a dynamic evolutionary history. Cancers (Basel) 2021; 13: doi:10.3390/cancers13092044.
doi: 10.3390/cancers13092044
Klein E, Hau AC, Oudin A, et al. Glioblastoma organoids: pre-clinical applications and challenges in the context of immunotherapy. Front Oncol 2020; 10:604121.
Pine AR, Cirigliano SM, Nicholson JG, et al. Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas. Cancer Discov 2020; 10:964–979.
Bleijs M, van de Wetering M, Clevers H, et al. Xenograft and organoid model systems in cancer research. EMBO J 2019; 38:e101654.
Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 2015; 21:1318–1325.
Woo XY, Giordano J, Srivastava A, et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 2021; 53:86–99.
Jacob F, Salinas RD, Zhang DY, et al. A patient-derived glioblastoma organoid model and Biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 2020; 180:188–204. e22.
Oudin A, Baus V, Barthelemy V, et al. Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors. STAR Protoc 2021; 2:100534.
Vaubel RA, Tian S, Remonde D, et al. Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res 2020; 26:1094–1104.
Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 2017; 49:1567–1575.
Golebiewska A, Hau AC, Oudin A, et al. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathol 2020; 140:919–949.
Dasgupta P, Balasubramanyian V, de Groot JF, et al. Preclinical models of low-grade gliomas. Cancers (Basel) 2023; 15: doi:10.3390/cancers15030596.
doi: 10.3390/cancers15030596
Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501:346–354.
Singh M, Murriel CL, Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res 2012; 72:2695–2700.
Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987; 52:206–211.
Read RD, Cavenee WK, Furnari FB, et al. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet 2009; 5:e1000374.
Sousa-Nunes R, Cheng LY, Gould AP. Regulating neural proliferation in the Drosophila CNS. Curr Opin Neurobiol 2010; 20:50–57.
Sarmiento BE, Callegari S, Ghotme KA, et al. Patient-derived xenotransplant of CNS neoplasms in zebrafish: a systematic review. Cells 2022; 11:1204.
Wrobel JK, Najafi S, Ayhan S, et al. Rapid in vivo validation of HDAC inhibitor-based treatments in neuroblastoma zebrafish xenografts. Pharmaceuticals (Basel) 2020; 13: doi:10.3390/ph13110345.
doi: 10.3390/ph13110345
Tucker ER, George S, Angelini P, et al. The promise of patient-derived preclinical models to accelerate the implementation of personalised medicine for children with neuroblastoma. J Pers Med 2021; 11: doi:10.3390/jpm11040248.
doi: 10.3390/jpm11040248
Hamilton L, Astell KR, Velikova G, et al. A zebrafish live imaging model reveals differential responses of microglia toward glioblastoma cells in vivo. Zebrafish 2016; 13:523–534.
Pudelko L, Edwards S, Balan M, et al. An orthotopic glioblastoma animal model suitable for high-throughput screenings. Neuro Oncol 2018; 20:1475–1484.
Stewart AM, Braubach O, Spitsbergen J, et al. Zebrafish models for translational neuroscience research: from tank to bedside. Trends Neurosci 2014; 37:264–278.
Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer 2018; 18:407–418.
Kenerson HL, Sullivan KM, Seo YD, et al. Tumor slice culture as a biologic surrogate of human cancer. Ann Transl Med 2020; 8:114.
Nishida-Aoki N, Bondesson AJ, Gujral TS. Measuring real-time drug response in organotypic tumor tissue slices. J Vis Exp 2020; (159): doi:10.3791/61036.
doi: 10.3791/61036
Stockslager MA, Malinowski S, Touat M, et al. Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Rep 2021; 37:109788.
Morelli M, Lessi F, Barachini S, et al. Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response early. Front Oncol 2022; 12:969812.
Lukina MM, Dudenkova VV, Ignatova NI, et al. Metabolic cofactors NAD(P)H and FAD as potential indicators of cancer cell response to chemotherapy with paclitaxel. Biochim Biophys Acta Gen Subj 2018; 1862:1693–1700.
Kolenc OI, Quinn KP. Evaluating cell metabolism through autofluorescence imaging of NAD(P)H and FAD. Antioxid Redox Signal 2019; 30:875–889.
Ibarrola-Villava M, Cervantes A, Bardelli A. Preclinical models for precision oncology. Biochim Biophys Acta Rev Cancer 2018; 1870:239–246.
Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014; 345:1247125.
Li M, Izpisua Belmonte JC. Organoids – preclinical models of human disease. N Engl J Med 2019; 380:569–579.
Bhagat J, Zang L, Nishimura N, et al. Zebrafish: an emerging model to study microplastic and nanoplastic toxicity. Sci Total Environ 2020; 728:138707.
Zhang Y, Chen M, Chen C. Using the zebrafish as a genetic model to study erythropoiesis. Int J Mol Sci 2021; 22: doi:10.3390/ijms221910475.
doi: 10.3390/ijms221910475
Humpel C. Organotypic brain slice cultures: Aa review. Neuroscience 2015; 305:86–98.
Siwczak F, Hiller C, Pfannkuche H, et al. Culture of vibrating microtome tissue slices as a 3D model in biomedical research. J Biol Eng 2023; 17:36.
Gould SE, Junttila MR, de Sauvage FJ. Translational value of mouse models in oncology drug development. Nat Med 2015; 21:431–439.